Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of “Hold” by Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been given a consensus recommendation of “Hold” by the five analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $9.40.

A number of equities research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, February 28th. Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $10.00 to $11.00 in a research report on Wednesday, December 17th.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Ben R. Taylor sold 13,426 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $3.08, for a total value of $41,352.08. Following the transaction, the chief financial officer directly owned 1,195,349 shares in the company, valued at approximately $3,681,674.92. This trade represents a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total transaction of $924,000.00. Following the transaction, the director owned 6,429,863 shares in the company, valued at $27,005,424.60. This represents a 3.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 599,212 shares of company stock valued at $2,562,550. Insiders own 8.43% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Recursion Pharmaceuticals by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after purchasing an additional 7,407,606 shares during the period. ARK Investment Management LLC raised its stake in shares of Recursion Pharmaceuticals by 11.2% in the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after buying an additional 3,771,357 shares during the period. State Street Corp lifted its position in shares of Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after buying an additional 7,064,963 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Recursion Pharmaceuticals by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock valued at $44,731,000 after acquiring an additional 1,310,695 shares during the period. Finally, Norges Bank bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $23,473,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $3.46 on Monday. The firm’s 50-day moving average price is $4.10 and its 200-day moving average price is $4.63. Recursion Pharmaceuticals has a 52-week low of $2.98 and a 52-week high of $7.18. The company has a market cap of $1.80 billion, a PE ratio of -2.34 and a beta of 0.97. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The firm had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $24.56 million. During the same period in the previous year, the company earned ($0.53) earnings per share. The firm’s quarterly revenue was up 671.7% on a year-over-year basis. As a group, analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.